Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
BMC Cancer|December 21, 2014
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocolShibani Nicum, Corran Roberts, Lucy Boyle, et al.
Chemical Communications (Cambridge, England)|June 19, 2015
Copper(I) complexes as alternatives to iridium(III) complexes for highly efficient oxygen sensingSantiago Medina-Rodríguez, Francisco J Orriach-Fernández, Christopher Poole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2018
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II TrialMothaffar Rimawi, Jean-Marc Ferrero, Juan de la Haba-Rodriguez, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancerBruno Reigner, Toru Watanabe, Johannes Schüller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2016
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive RelapseIgnace Vergote, Deborah Armstrong, Giovanni Scambia, et al.
JACC. Cardiovascular Imaging|March 20, 2026
Biological, Radiological, and Clinical Significance of Spotty Calcification in Coronary Artery Disease: A State-of-the-Art ReviewSina Fathieh, Michael P Gray, Max Kirkby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials groupGraham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
Pageof 3